Effective adaptive immune responses depend on activation of CD4+ T cells via the presentation of antigen peptides in the context of major histocompatibility complex (MHC) class II. The structure of an antigen strongly influences its processing within the endolysosome and potentially controls the identity of peptides that are presented to T cells. A recombinant immunotoxin, comprising exotoxin A domain III (PE-III) from and a cancer-specific antibody fragment, has been developed to manage cancer, but its effectiveness is limited by the induction of neutralizing antibodies. Here, we observed that this immunogenicity is substantially reduced by substituting six residues within PE-III. Although these substitutions targeted T-cell epitopes, we demonstrate that reduced conformational stability and protease resistance were responsible for the reduced antibody titer. Analysis of mouse T-cell responses coupled with biophysical studies on single-substitution versions of PE-III suggested that modest but comprehensible changes in T-cell priming can dramatically perturb antibody production. The most strongly responsive PE-III epitope was well-predicted by a structure-based algorithm. In summary, single-residue substitutions can drastically alter the processing and immunogenicity of PE-III but have only modest effects on CD4+ T-cell priming in mice. Our findings highlight the importance of structure-based processing constraints for accurate epitope prediction.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433056PMC
http://dx.doi.org/10.1074/jbc.RA118.006704DOI Listing

Publication Analysis

Top Keywords

exotoxin domain
8
domain iii
8
t-cell epitopes
8
t-cell priming
8
t-cell
5
pe-iii
5
deimmunizing substitutions
4
substitutions exotoxin
4
iii perturb
4
perturb antigen
4

Similar Publications

Background: Developing effective targeted treatment approaches to overcome drug resistance remains a crucial goal in cancer research. Immunotoxins have dual functionality in cancer detection and targeted therapy.

Objective: This study aimed to engineer a recombinant chimeric fusion protein by combining a nanobody-targeting domain with an exotoxin effector domain.

View Article and Find Full Text PDF
Article Synopsis
  • - TROP-2, a protein linked to various types of cancer, is a potential target for new cancer treatments, specifically antibody-drug conjugates (ADCs), but their effectiveness against solid tumors is limited due to issues like poor penetration.
  • - Researchers developed a small, stable immunotoxin using a shark-derived antibody known as VNAR, which has better tissue penetration properties than traditional antibodies.
  • - The study identified a specific VNAR, called VNAR-5G8, which binds effectively to TROP-2 and created a recombinant immunotoxin (5G8-PE38) that showed strong anti-tumor activity, suggesting its potential as a cancer therapy option.
View Article and Find Full Text PDF

Characterization of Kunitz-Domain Anticoagulation Peptides Derived from Exotoxin Protein F6W77.

Toxins (Basel)

October 2024

Institute of Biomedicine, Hubei Key Laboratory of Embryonic Stem Cell Research, and Hubei Key Laboratory of Wudang Local Chinese Medicine Research, College of Basic Medicine, Hubei University of Medicine, Shiyan 442000, China.

Article Synopsis
  • Recent research suggests that the coagulation system in mammals helps defend against bacterial infections by trapping bacteria in clots and producing antimicrobial peptides.
  • A study identified a new bacterial exotoxin called F6W77, which contains five Kunitz-type domains that have similarities to animal but not plant proteins.
  • Evaluation of these Kunitz-domain peptides revealed that KABP1 and KABP5 effectively inhibit specific coagulation factors, indicating a new mechanism by which bacteria may evade the host's defense system.
View Article and Find Full Text PDF

Cancer is a global health problem despite the most developed therapeutic modalities. The delivery of specific therapeutic agents to a target increases the effectiveness of cancer treatment by reducing side effects and post-treatment issues. Our aim in this study was to design a recombinant protein consisting of nanobody molecules and exotoxin that targets the surface GRP78 receptor on tumor cells.

View Article and Find Full Text PDF

exotoxin A as a novel allergen induced Non-T2 inflammation in a murine model of steroid-insensitive asthma.

Heliyon

September 2024

, The Second Affiliated Hospital, Guangdong Provincial Key Laboratory of Allergy & Immunology, The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, 250 Changgang Road East, Guangzhou, 510260, China.

Article Synopsis
  • The study explores the allergenic potential of exotoxin A (PEA) and its connection to asthma, highlighting its unclear role in asthma pathogenesis despite causing allergic reactions.
  • Researchers used a modified PEA that eliminates non-specific toxicity to examine its impact on asthmatic patients and mice, measuring PEA-specific IgE levels and conducting various assays to understand its effects.
  • The results showed that PEA sensitizes some asthmatic patients and can induce steroid-resistant asthma in mice, suggesting PEA's significant role in asthma development and the need for its consideration in clinical diagnosis and treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!